Dr. Garissino on Combinations With Immune Checkpoint Inhibitors in NSCLC

Marina Chiara Garassino, MD
Published: Tuesday, Oct 31, 2017



Marina Chiara Garassino, MD, medical consultant, Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, discusses combinations with immune checkpoint inhibitors in non–small cell lung cancer (NSCLC).

Garassino says that the future of immunotherapy in NSCLC lies in combinations.

In the future, treatment will be based on phenotype, says Garissino. The 3 phenotypes that are known right now in NSCLC are inflamed and immune-excluded, and immune-desert.
 


Marina Chiara Garassino, MD, medical consultant, Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, discusses combinations with immune checkpoint inhibitors in non–small cell lung cancer (NSCLC).

Garassino says that the future of immunotherapy in NSCLC lies in combinations.

In the future, treatment will be based on phenotype, says Garissino. The 3 phenotypes that are known right now in NSCLC are inflamed and immune-excluded, and immune-desert.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x